These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3572801)

  • 1. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man.
    Kawai S; Nieman LK; Brandon DD; Udelsman R; Loriaux DL; Chrousos GP
    J Pharmacol Exp Ther; 1987 May; 241(2):401-6. PubMed ID: 3572801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit.
    Wang G; Aedo AR; Cekan SZ
    Arzneimittelforschung; 1986 Jun; 36(6):936-8. PubMed ID: 3741527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of RU 486 and its active metabolites in humans].
    Földesi I; Falkay G; Kovács L
    Acta Pharm Hung; 1994 Jan; 64(1):17-21. PubMed ID: 8023681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
    Heikinheimo O; Kontula K; Croxatto H; Spitz I; Luukkainen T; Lähteenmäki P
    J Steroid Biochem; 1987 Feb; 26(2):279-84. PubMed ID: 3560943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism of RU 486.
    Lähteenmäki P; Heikinheimo O; Croxatto H; Spitz I; Shoupe D; Birgerson L; Luukkainen T
    J Steroid Biochem; 1987; 27(4-6):859-63. PubMed ID: 3695508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.
    Bertagna X; Bertagna C; Laudat MH; Husson JM; Girard F; Luton JP
    J Clin Endocrinol Metab; 1986 Sep; 63(3):639-43. PubMed ID: 3734034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radioreceptor assay for determination of the anti-progestogen, RU-486 and its active metabolites in the blood].
    Földesi I; Falkay G; Kovács L
    Acta Pharm Hung; 1992 Nov; 62(6):271-7. PubMed ID: 1488912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.
    Nieman LK; Chrousos GP; Kellner C; Spitz IM; Nisula BC; Cutler GB; Merriam GR; Bardin CW; Loriaux DL
    J Clin Endocrinol Metab; 1985 Sep; 61(3):536-40. PubMed ID: 2991327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiprogesterone and antiglucocorticoid actions of RU 486 on rabbit mammary gland explant cultures. Evidence for a persistent inhibitory action of residual progesterone upon the mammary tissue.
    Jahn GA; Houdebine LM; Djiane J
    J Steroid Biochem; 1987 Oct; 28(4):371-7. PubMed ID: 3669658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin release-inhibitory effects of progesterone, megestrol acetate, and mifepristone (RU 38486) by cultured rat pituitary tumor cells.
    Lamberts SW; van Koetsveld P; Verleun T
    Cancer Res; 1987 Jul; 47(14):3667-71. PubMed ID: 3594432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of the anti-progestin RU-486 to rat ovary steroid receptors.
    Schreiber JR; Hsueh AJ; Baulieu EE
    Contraception; 1983 Jul; 28(1):77-85. PubMed ID: 6627946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy].
    Herrmann W; Wyss R; Riondel A; Philibert D; Teutsch G; Sakiz E; Baulieu EE
    C R Seances Acad Sci III; 1982 May; 294(18):933-8. PubMed ID: 6814714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and salivary 6beta-hydroxycortisol measurements for assessing adrenocortical activity in patients with adrenocortical adenomas.
    Varga I; Jakab C; Szücs N; Patócs A; Tóth M; Kiss R; Gláz E; Rácz K
    Horm Metab Res; 2003 Jul; 35(7):421-6. PubMed ID: 12931273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental and hormonal regulation of progesterone receptor A-form expression in female mouse lung in vivo: interaction with glucocorticoid receptors.
    Shao R; Egecioglu E; Weijdegård B; Ljungström K; Ling C; Fernandez-Rodriguez J; Billig H
    J Endocrinol; 2006 Sep; 190(3):857-70. PubMed ID: 17003286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiglucocorticoid action of RU 486].
    Bertagna X
    Ann Endocrinol (Paris); 1989; 50(3):208-17. PubMed ID: 2554782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New analogues of mifepristone with more dissociated antiprogesterone activities.
    Philibert D; Hardy M; Gaillard-Moguilewsky M; Nique F; Tournemine C; Nédélec L
    J Steroid Biochem; 1989; 34(1-6):413-7. PubMed ID: 2560520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of RU 486 and its demethylated metabolites in humans.
    Heikinheimo O; Haukkamaa M; Lähteenmäki P
    J Clin Endocrinol Metab; 1989 Feb; 68(2):270-5. PubMed ID: 2918046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study.
    Földesi I; Falkay G; Kovács L
    Contraception; 1996 Jul; 54(1):27-32. PubMed ID: 8804805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3H-labelled RU 38486: characterization of binding sites in human uterine cytosol.
    Heubner A; Pollow K; Manz B; Grill HJ; Belovsky O
    J Clin Chem Clin Biochem; 1985 May; 23(5):265-76. PubMed ID: 4020325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.